Table 1 Demographics of study population
Variables | Healthy controls (n = 20 | 18.2%) | LTR (n = 31 | 28.2%) | KTR (n = 59 | 53.6%) | LTR vs KTR | Total SOT (N = 90) | ||||
|---|---|---|---|---|---|---|---|---|---|
General | n | % | n | % | n | % | p-value* | n | % |
Sex (male) | 13 | 65.0 | 21 | 67.7 | 33 | 55.9 | 0.389 | 54 | 60.0 |
Age | 0.039 | ||||||||
<50 years | 0 | 0.0 | 12 | 38.7 | 11 | 18.6 | 23 | 25.6 | |
50-70 years | 20 | 100.0 | 18 | 58.1 | 38 | 64.4 | 56 | 62.2 | |
>70 years | 0 | 0.0 | 1 | 3.2 | 10 | 16.9 | 11 | 12.2 | |
BMI | 0.183 | ||||||||
Standard | --- | --- | 19 | 61.3 | 26 | 44.1 | 45 | 50.0 | |
Overweight | --- | --- | 12 | 38.7 | 33 | 55.9 | 45 | 50.0 | |
Ethnicity | 0.423 | ||||||||
European | --- | --- | 28 | 90.3 | 48 | 81.4 | 76 | 84.4 | |
African | --- | --- | 3 | 9.7 | 9 | 15.3 | 12 | 13.3 | |
Other | --- | --- | 0 | 0.0 | 2 | 3.4 | 2 | 2.2 | |
Time after transplant | <0.001 | ||||||||
>10 years | NA | NA | 9 | 29.0 | 28 | 47.5 | 37 | 41.1 | |
3-10 years | NA | NA | 14 | 45.2 | 18 | 30.5 | 32 | 35.6 | |
<3 years | NA | NA | 8 | 25.8 | 13 | 22.0 | 21 | 23.3 | |
Transplant rank | 0.450 | ||||||||
One | NA | NA | 30 | 96.8 | 53 | 89.8 | 83 | 92.2 | |
Two or more | NA | NA | 1 | 3.2 | 6 | 10.2 | 7 | 7.8 | |
Comorbidities | |||||||||
Diabetes | 0 | 0.0 | 13 | 41.9 | 22 | 37.3 | 0.840 | 35 | 38.9 |
HTA | 5 | 25.0 | 20 | 64.5 | 49 | 83.1 | 0.087 | 69 | 67.7 |
CVD | 0 | 0.0 | 2 | 6.5 | 16 | 27.1 | 0.040 | 18 | 20.0 |
eGFR <30 ml/min/1.73 m2 | 0 | 0.0 | 2 | 6.5 | 8 | 13.6 | 0.505 | 10 | 11.1 |
Non-invasive cancer | 1 | 5.0 | 1 | 3.2 | 15 | 25.4 | 0.020 | 16 | 17.8 |
Treatment | |||||||||
CS | NA | NA | 31 | 100.0 | 46 | 78.0 | 0.012 | 77 | 85.6 |
AZA | NA | NA | 4 | 12.9 | 15 | 25.4 | 0.266 | 19 | 21.1 |
MMF | NA | NA | 16 | 51.6 | 30 | 50.8 | 0.999 | 46 | 51.1 |
FK506 | NA | NA | 31 | 100.0 | 40 | 67.8 | 0.001 | 71 | 78.9 |
CsA | NA | NA | 0 | 0.0 | 8 | 13.6 | 0.079 | 8 | 8.9 |
Evero | NA | NA | 0 | 0.0 | 14 | 23.7 | 0.008 | 14 | 15.6 |
Induction | <0.001 | ||||||||
ATG | NA | NA | 28 | 100.0 | 18 | 31.6 | 46 | 54.1 | |
Anti-IL2R | NA | NA | 0 | 0.0 | 34 | 59.6 | 34 | 40.0 | |
OKT3 | NA | NA | 0 | 0.0 | 5 | 8.8 | 5 | 5.9 | |
Number of immunosuppressive treatments | 0.800 | ||||||||
Two | NA | NA | 11 | 35.5 | 24 | 40.7 | 35 | 38.9 | |
Three | NA | NA | 20 | 64.5 | 35 | 59.3 | 55 | 61.1 | |
